WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018024110) MG53 MUTANT, AND PREPARATION METHOD THEREFOR AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/024110 International Application No.: PCT/CN2017/093640
Publication Date: 08.02.2018 International Filing Date: 20.07.2017
IPC:
C07K 14/47 (2006.01) ,C12N 15/12 (2006.01) ,A61K 38/17 (2006.01) ,A61P 9/00 (2006.01) ,A61P 13/12 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
12
Genes encoding animal proteins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13
Drugs for disorders of the urinary system
12
of the kidneys
Applicants: PEKING UNIVERSITY[CN/CN]; NO. 5, Yiheyuan Road, Haidian District Beijing 100080, CN
Inventors: XIAO, Rui-ping; CN
LU, Fengxiang; CN
ZHANG, Yan; CN
GUO, Sile; CN
Agent: JUN HE LAW OFFICES; 20/F, China Resources Building 8 Jianguomenbei Avenue Beijing 100005, CN
Priority Data:
201610621989.701.08.2016CN
201610847346.423.09.2016CN
201710560975.311.07.2017CN
Title (EN) MG53 MUTANT, AND PREPARATION METHOD THEREFOR AND USES THEREOF
(FR) MUTANT DE MG53, SON PROCÉDÉ DE PRÉPARATION ET SES UTILISATIONS
(ZH) MG53突变体及其制备方法和用途
Abstract:
(EN) An MG53 mutant. A coiled-coil-SPRY region of the wild-type MG53 is provided with amino acids among which at least one amino acid is deleted and/or mutated to any other amino acid except serine or threonine. The prevent invention comprises a pharmaceutical composition of the MG53 mutant, a nucleic acid for coding the MG53 mutant, and the preparation method for the MG53 mutant, and uses of the MG53 mutant in the preparation of drugs for treating heart diseases, cerebrovascular diseases in diabetes mellitus, eye complications in diabetes mellitus, neuropathies in diabetes mellitus, diabetic foot diseases, kidney diseases and diseases related to cell and/or tissue damages. Particularly, the MG53 mutant can avoid or reduce metabolic side effects brought by the wild-type MG53, such as insulin resistance, obesity, diabetes mellitus, hypertension and dyslipidemia, while the heart diseases, the cerebrovascular diseases in diabetes mellitus, the eye complications in diabetes mellitus, neuropathies in diabetes mellitus, the diabetic foot diseases, the kidney diseases and the diseases related to cell and/or tissue damages are treated.
(FR) Un mutant de MG53. Une région de SPRY bispiralée du MG53 de type sauvage est pourvue d'acides aminés dont au moins un acide aminé est supprimé et/ou muté en tout autre acide aminé à l'exception de la sérine ou de la thréonine. La présente invention comprend une composition pharmaceutique du mutant MG53, un acide nucléique pour le codage du mutant MG53, et sur le procédé de préparation du mutant de MG53, et sur des utilisations du mutant de MG53 dans la préparation de médicaments pour le traitement de maladies cardiaques, des maladies cérébrovasculaires dans le diabète sucré, des complications oculaires du diabète sucré, des neuropathies du diabète sucré, des maladies du pied diabétique, des maladies rénales et des maladies liées à des lésions cellulaires et/ou tissulaires. En particulier, le mutant de MG53 peut éviter ou réduire les effets secondaires métaboliques provoqués par le MG53 de type sauvage, tels que la résistance à l'insuline, l'obésité, le diabète sucré, l'hypertension et la dyslipidémie, tandis que les maladies cardiaques, les maladies cérébrovasculaires du diabète sucré, les complications oculaires du diabète sucré, les neuropathies du diabète sucré, les maladies du pied diabétique, les maladies rénales et les maladies liées aux lésions cellulaires et/ou tissulaires sont traitées.
(ZH) 一种MG53突变体,在野生型MG53的coiled-coil-SPRY区域内具有至少一个丝氨酸缺失和/或突变为任何其他非丝氨酸或苏氨酸的氨基酸。包括所述MG53突变体的药物组合物;编码所述MG53突变体的核酸;所述MG53突变体的制备方法;所述MG53突变体在制备用于治疗心脏疾病、糖尿病脑血管疾病、糖尿病眼部并发症、糖尿病神经病变、糖尿病足、肾脏疾病、与细胞和/或组织损伤相关疾病的药物中的用途,特别地,所述MG53突变体在治疗心脏疾病、糖尿病脑血管疾病、糖尿病眼部并发症、糖尿病神经病变、糖尿病足、肾脏疾病、与细胞和/或组织损伤相关疾病的同时,能够避免或减少野生型MG53所带来的代谢类副作用,例如,胰岛素抵抗、肥胖、糖尿病、高血压、血脂异常等。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)